Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pomalidomide, quantity: 4 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; maltodextrin; sodium stearylfumarate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; indigo blue; erythrosine; shellac - pomalidomide sandoz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalidomide sandoz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior threatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pomalidomide, quantity: 3 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; maltodextrin; sodium stearylfumarate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; indigo blue; shellac - pomalidomide sandoz, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalidomide sandoz, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior threatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

European Union - English - EMA (European Medicines Agency)

sandoz gmbh - aripiprazole - schizophrenia; bipolar disorder - psycholeptics - aripiprazole sandoz is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. aripiprazole sandoz is indicated for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. aripiprazole sandoz is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in bipolar i disorder in adolescents aged 13 years and older.,

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol - bortezomib sandoz, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib sandoz, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib sandoz is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib sandoz in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Canada - English - Health Canada

fresenius kabi canada ltd - zinc (zinc sulfate) - solution - 1mg - zinc (zinc sulfate) 1mg

Canada - English - Health Canada

fresenius kabi canada ltd - zinc (zinc sulfate) - solution - 5mg - zinc (zinc sulfate) 5mg

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 10mg - tablet - 10 mg - active: aripiprazole 10mg excipient: hyprolose iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 15mg - tablet - 15 mg - active: aripiprazole 15mg excipient: hyprolose iron oxide yellow lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 20mg - tablet - 20 mg - active: aripiprazole 20mg excipient: hyprolose lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - aripiprazole 30mg - tablet - 30 mg - active: aripiprazole 30mg excipient: hyprolose iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.